(Q35163896)

6 August 2017

Outcomes of osteomyelitis among patients treated with outpatient parenteral antimicrobial therapy (English)

1 reference

6 August 2017

1 reference

Alan D Tice

1

1 reference

6 August 2017

Pamela A Hoaglund

series ordinal

2

1 reference

6 August 2017

David A Shoultz

series ordinal

3

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 June 2003

1 reference

American Journal of Medicine

6 August 2017

1 reference

6 August 2017

114

1 reference

6 August 2017

9

1 reference

6 August 2017

723-728

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900231-6

6 August 2017

1 reference

Osteomyelitis: the past decade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900231-6

Outpatient parenteral antibiotic therapy. Management of serious infections. Part II: Amenable infections and models for delivery. Osteomyelitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900231-6

Antibiotic-impregnated cement and beads for orthopedic infections.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900231-6

Outpatient parenteral antimicrobial therapy for osteomyelitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900231-6

Antimicrobial treatment of chronic osteomyelitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900231-6

Ceftriaxone therapy for staphylococcal osteomyelitis: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900231-6

Outpatient parenteral antibiotic therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900231-6

Staging and staging application in osteomyelitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900231-6

Osteomyelitis: A Review of Clinical Features, Therapeutic Considerations and Unusual Aspects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900231-6

Osteomyelitis: a review of clinical features, therapeutic considerations and unusual aspects (second of three parts).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900231-6

Osteomyelitis: a review of clinical features, therapeutic considerations and unusual aspects. 3. Osteomyelitis associated with vascular insufficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900231-6

Osteomyelitis in infants and children. A review of 163 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900231-6

Long-term follow-up of ambulatory management of osteomyelitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900231-6

Simplified treatment of acute staphylococcal osteomyelitis of childhood. The Finnish Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900231-6

Osteomyelitis in the feet of diabetic patients. Long-term results, prognostic factors, and the role of antimicrobial and surgical therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900231-6

Ofloxacin versus parenteral therapy for chronic osteomyelitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900231-6

Quinolones and osteomyelitis: state-of-the-art.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900231-6

Systematic review and meta-analysis of antibiotic therapy for bone and joint infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900231-6

Antimicrobial therapy for chronic osteomyelitis in adults: role of the quinolones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900231-6

Evaluation of new anti-infective drugs for the treatment of selected infections of the skin and skin structure. Infectious Diseases Society of America and the Food and Drug Administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900231-6

Ambulatory antimicrobial use: the value of an outcomes registry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900231-6

An office model of outpatient parenteral antibiotic therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900231-6

Practice guidelines for community-based parenteral anti-infective therapy. ISDA Practice Guidelines Committee

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900231-6

Peripheral arterial disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900231-6

Rates of lower-extremity amputation and arterial reconstruction in the United States, 1979 to 1996

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900231-6

Osteomyelitis of the foot in diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900231-6

Can aggressive treatment of diabetic foot infections reduce the need for above-ankle amputation?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900231-6

Outcome of diabetic foot infections treated conservatively: a retrospective cohort study with long-term follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900231-6

Quality of life following lower limb amputation for peripheral arterial disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900231-6

New developments in diagnosis and treatment of infection in orthopedic implants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900231-6

Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900231-6

Recurrent Staphylococcus aureus bacteremia: pulsed-field gel electrophoresis findings in 29 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900231-6

Infective endocarditis due to Staphylococcus aureus: 59 prospectively identified cases with follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900231-6

Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900231-6

Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900231-6

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900231-6

Ambulatory use of parenteral antibacterials: contemporary perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900231-6

10.1016/S0002-9343(03)00231-6

7 January 2021

Identifiers

DOI

1 reference

6 August 2017

1 reference